Purdue Pharma, a bankrupt drugmaker, has submitted a fresh bankruptcy plan to advance a proposed opioid settlement worth at least $7.4 billion, following a setback in the U.S. Supreme Court. The goal of these payments is to resolve multiple lawsuits alleging that OxyContin, a pain medication produced by the company, played a significant role in the widespread opioid addiction crisis in the United States. The plan outlines how the funds will be distributed among states, local authorities, and individuals impacted by the crisis. The company anticipates strong support from creditors for the proposed deal, and plans to commence the voting process and decisions with creditors in May. Following this, the plan will be presented to a U.S. bankruptcy judge for final approval. The revised bankruptcy plan comes after the Supreme Court invalidated Purdue's previous attempt to settle the lawsuits, which would have granted the Sackler family civil immunity from opioid litigation. Purdue's Chairman, Steve Miller, expressed satisfaction with the lengthy negotiations that have led to an improved deal that will provide much-needed support to communities affected by opioid addiction. The new settlement offers creditors the choice to participate and receive payments, allowing those who opt out to pursue legal action against the Sacklers. The Sacklers, who have raised their contribution to between $6.5 billion and $7 billion for the updated settlement, have asserted their readiness to defend themselves in court against any lawsuits.